4D Molecular Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FDMT | RGNX | IRD | DSGN | SRZN | MGTX | |
|---|---|---|---|---|---|---|
| Market cap | 678.40M | 508.96M | 355.25M | 665.24M | 553.72M | 904.72M |
| P/E (TTM) | — | — | — | — | — | 10.8 |
| Forward P/E | -3.0 | -2.6 | -6.0 | -6.6 | -7.6 | -6.2 |
| Price/book | 1.7 | 5.8 | -27.2 | 3.3 | -1.7 | 4.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +13.70% | −34.28% | +85.38% | +57.86% | +142.51% | +10.96% |
| Today | +2.76% | +1.05% | +8.65% | +2.80% | +5.08% | −1.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All FDMT news ›4DMT to Participate in Upcoming Investor Conferences
The Manila Times EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with…
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026): Trial and Patient Cohort Overview Phase 2b Efficacy Results Through 2 Years: Safety Data for Phase 3 Dose in Overall PRISM Phase 1/2a & 2b Clinical Trial (n=71) The…
Analysts’ Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Biodesix (BDSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 4D Molecular Therapeutics (FDMT) and Biodesix (BDSX) with bullish sentiments. 4D Molecular Therapeutics (FDMT) In a report released today,…
Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & IDEAYA Biosciences (NASDAQ:IDYA)
Posted by Michael Walen on Oct 24th, 2026 IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast…
4D Molecular Therapeutics Rings the Nasdaq Stock Market Closing Bell
4D Molecular Therapeutics (Nasdaq: FDMT), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, visits…
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day October 21, 2026 10:30 AM EDT Julian Pei - Head of Investor Relations & Corporate FinanceDavid Kirn - Co-Founder, President, CEO & DirectorDhaval DesaiChristopher Simms - Chief…
FDMT: PRISM supports 4D-150’s backbone-therapy thesis as global Phase 3 results approach in 2027
TradingView FDMT: PRISM supports 4D-150’s backbone-therapy thesis as global Phase 3 results approach in 2027 4D-150’s PRISM data showed stable vision and anatomy with lower injection burden, supporting
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90
Posted by Defense World Staff on Oct 13th, 2026 Read Our Latest Research Report on 4D Molecular Therapeutics 4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious…
4D Molecular Therapeutics Officer David Kirn Files Form 144 for Sale of 58,333 Shares
Kalkine Media On October 5, 2026, David Kirn, an officer at 4D Molecular Therapeutics, Inc., submitted a Form 144 notice for the proposed sale of 58,333 Class A Common shares valued at $753,662.36. The transaction
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- nasdaq.com2
- seekingalpha.com2
- themarketsdaily.com2
- defenseworld.net1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.